Monitoring (RBM). The monitoring plan provides a structured approach to ensure subject safety, data integrity, and compliance with regulatory requirements, while optimizing monitoring resources through a risk-based strategy.

Scope

This SOP applies to sponsors, CROs, clinical research associates (CRAs), monitors, and investigators involved in planning and executing clinical trial monitoring activities. It covers development of a monitoring strategy, RBM methodology, central monitoring integration, onsite and remote monitoring schedules, escalation procedures, and documentation requirements.

Responsibilities

• Sponsor: Oversees monitoring plan design, approval, and compliance with regulatory requirements.
• Clinical Operations Manager: Develops monitoring strategy, incorporating RBM principles.
• CRA/Monitor: Executes monitoring plan, documents findings, and ensures corrective actions.
• Data Manager: Provides risk metrics and key risk indicators (KRIs) for RBM integration.
• Principal Investigator (PI): Ensures site compliance and facilitates monitoring visits.
• QA Officer: Audits monitoring plans and verifies adherence during inspections.

Accountability

The sponsor is accountable for ensuring that a comprehensive monitoring plan is developed, risk-based elements are integrated, and monitoring activities are aligned with regulatory expectations (ICH GCP E6 R2, FDA guidance, EMA RBM reflection paper).

Procedure

1. Risk Assessment
Conduct trial-level risk assessment before drafting the monitoring plan.
Identify critical data and processes impacting subject safety and data integrity.
Define Key Risk Indicators (KRIs) such as SAE reporting timelines, data entry lag, and protocol deviations.

2. Monitoring Strategy Development
Choose appropriate monitoring model: 100% SDV, targeted SDV, centralized monitoring, or hybrid.
Document rationale for selected strategy in the Monitoring Strategy Log (Annexure-1).

3. RBM Methodology Integration
Incorporate centralized data review dashboards for trend analysis.
Use KRIs and Quality Tolerance Limits (QTLs) to guide monitoring intensity.
Trigger escalations when KRIs exceed predefined thresholds.

4. Monitoring Visit Planning
Define frequency of onsite and remote visits based on risk profile.
Schedule visits proportionally to enrollment, data volume, and site history.
Record planned visits in Monitoring Visit Schedule (Annexure-2).

5. Monitoring Tools and Templates
Use standardized checklists and monitoring report templates.
Ensure all tools are stored in TMF for inspection readiness.

6. Execution and Documentation
CRAs execute visits, review source data, verify CRF entries, and assess protocol compliance.
Findings are documented in Monitoring Visit Reports (Annexure-3).
Serious issues must be escalated to Clinical Operations Manager within 24 hours.

7. Escalation and CAPA
Escalate major protocol deviations, repeated non-compliance, or GCP violations.
CAPA plans must be developed, implemented, and tracked.
Document escalations in Escalation Log (Annexure-4).

8. Review and Updates
Monitoring plan must be reviewed at least annually or when significant protocol changes occur.
Updates must be version controlled and filed in TMF.

9. Archiving
Archive final monitoring plans, reports, logs, and escalations for at least 15 years.
Maintain retrievability for regulatory inspections.

Abbreviations

• SOP: Standard Operating Procedure
• PI: Principal Investigator
• CRA: Clinical Research Associate
• CRO: Clinical Research Organization
• QA: Quality Assurance
• TMF: Trial Master File
• ISF: Investigator Site File
• RBM: Risk-Based Monitoring
• KRI: Key Risk Indicator
• QTL: Quality Tolerance Limit
• SDV: Source Data Verification

Documents

1. Monitoring Strategy Log (Annexure-1)
2. Monitoring Visit Schedule (Annexure-2)
3. Monitoring Visit Report (Annexure-3)
4. Escalation Log (Annexure-4)

References

• ICH E6(R2) – Good Clinical Practice
• FDA – Guidance on Risk-Based Monitoring
• EMA – Risk-Based Quality Management in Clinical Trials
• CDSCO – Monitoring Requirements for Clinical Trials
• WHO – Monitoring Guidelines in Clinical Research

Version: 1.0

Approval Section

Prepared By	Rajesh Kumar, Clinical Operations Manager
Checked By	Sunita Reddy, QA Officer
Approved By	Dr. Anil Sharma, Principal Investigator

Annexures

Annexure-1: Monitoring Strategy Log

Date	Trial	Strategy	Justification	Approved By
10/09/2025	Trial A	Hybrid RBM	High enrollment, moderate risk	Sponsor
12/09/2025	Trial B	Centralized + Targeted	Low risk endpoints	QA Officer

Annexure-2: Monitoring Visit Schedule

Site	Planned Visit Date	Type	CRA Assigned	Status
Site 001	15/09/2025	Onsite	Ravi Kumar	Planned
Site 002	18/09/2025	Remote	Meena Sharma	Scheduled

Annexure-3: Monitoring Visit Report

Date	Site	Key Findings	Deviations	Action Required
20/09/2025	Site 001	CRF entries delayed	2	Follow-up training
22/09/2025	Site 002	Drug accountability incomplete	1	Immediate correction

Annexure-4: Escalation Log

Date	Issue	Escalated To	Resolution	Closed By
23/09/2025	Repeated late SAE reporting	Sponsor	CAPA implemented	QA Officer
24/09/2025	Multiple protocol deviations	Clinical Ops Manager	Site retrained	Sponsor

Revision History

Revision Date	Revision No.	Revision Details	Reason for Revision	Approved By
26/08/2025	00	Initial version	New SOP creation	Head, Clinical Operations

For more SOPs visit: Pharma SOP